Crohn's disease

An FDA approval of an autoinjector for ustekinumab may make self‑injection easier and more convenient for people with Crohn’s disease or ulcerative colitis who use this biologic. Changes in delivery format can also...

An obituary noting a life-long struggle with Crohn’s disease highlights the personal and community impact of IBD and links readers to a charity (Crohn’s and Colitis Canada) for donations.

New phase IIb trial results suggest an anti‑TL1A antibody (duvakitug) produced measurable benefit in both Crohn’s disease and ulcerative colitis, which could lead to a new treatment option if later phase III trials...

Market growth and industry activity can affect drug availability, prices, and the pace of new treatments or diagnostics reaching patients. Increased investment in biomarkers and targeted therapies may lead to better...

People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.

The study tests whether fewer random biopsies are needed during surveillance colonoscopy with modern high-definition scopes — a question that could change how often biopsies are taken, affect procedure time, costs, and...

Early-phase trials test whether new treatments are safe and show biological activity. This study measures fecal calprotectin, a biomarker of intestinal inflammation, so it could provide early signals about whether ND-12...

People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...

Identifies specific gut bacteria and fecal bilirubin metabolites that may link microbial loss to increased oxidative burden in IBD; suggests new biomarker candidates and targets for functional follow-up.

The paper reports a novel small molecule (CA-23) that directly antagonizes CD28, reducing pathogenic T cell responses in preclinical IBD models and in cells from IBD donors. If validated, this represents a...

Patients and clinicians interested in Crohn’s disease should note a new company (Fibrx) is prioritizing drugs that directly target fibrosis and strictures — an area with few medical options today.

If validated, blood-based AI predictors of organ-specific aging might help flag organs aging faster in people with Crohn’s disease or other conditions, potentially enabling earlier monitoring or research into causes....

Recognizing eye inflammation as a possible early sign of IBD could shorten diagnostic delays and lead to earlier gastroenterology evaluation and treatment, which is especially important for children who often wait years...

This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...

The study uses generative AI and microbiome/RNA data to search for biomarkers of intestinal fibrosis in Crohn’s disease, which could help spot scarring earlier and potentially prevent worsening complications like...

This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.

If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...

A simple home test for urinary oxalate and Ox/Crea ratio could make monitoring more practical than 24-hour urine collections, helping prevent stone recurrence and allowing earlier treatment adjustments for people at...

Because it describes a severe new Crohn’s disease case temporally linked to COVID‑19, patients and clinicians should be aware that persistent or worsening GI symptoms after SARS‑CoV‑2 infection may merit investigation;...

This study suggests brain glymphatic function — a fluid-clearance system — may be altered in people with Crohn’s disease and could relate to inflammation and common neuropsychiatric symptoms like fatigue, anxiety,...

A company acquisition shifts R&D focus toward fibrosis and brings a Crohn’s‑targeted anti‑fibrotic (RXC008) into a new corporate owner, which could influence development speed and resources for therapies aimed at...

IgA vasculitis can be a rare adverse effect of anti-TNF therapy like infliximab and may mimic Crohn’s relapse, so recognizing it can prevent incorrect escalation of IBD treatment.

Many people on ustekinumab who lose response wonder whether increasing dosing frequency helps. This prospective study suggests that empiric intensification to every 4 or 6 weeks raised drug levels and was linked with...

Pregnant people with Crohn’s disease are often prescribed disease‑modifying therapies, yet clinical trial data in pregnancy are limited. Understanding real‑world medication use and potential drug–drug interactions helps...

An organoid platform that models epithelial injury and recovery could help researchers test treatments and biomarkers more precisely and at scale, accelerating work relevant to Crohn’s disease and other IBDs.

Based on the title and source metadata, this appears to be a case report related to Crohn's disease and Complications. The original article is from JAAD case reports.

Extraintestinal symptoms such as fatigue and joint pain significantly affect quality of life in Crohn's disease. This review suggests ustekinumab may help reduce fatigue and arthritis/arthralgia more than TNF antagonists...

The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...

Women with Crohn’s may experience menstrual changes, fertility concerns when disease is active, iron deficiency, and pain during sex—issues that can affect quality of life and reproductive planning.

Many people with IBD try dietary changes to manage symptoms. This review summarizes what published adult studies report and points toward whole-food and Mediterranean-style patterns as commonly supported approaches.

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from msn.com.

A local Pediatric IBD Day helps children, families and care teams connect, learn practical skills for daily life with IBD, and reduces the burden of travelling for specialized pediatric care. For families in...

If confirmed, a gut-derived strain of Lancefieldella parvula that rises with local inflammation could become a mucosal biomarker to help track disease severity or study inflammation mechanisms in IBD.

Hepatitis E can cause elevated liver enzymes in people with IBD on biologics or small molecules. This series found infections were acute and resolved without chronic infection, and advanced therapy could be restarted....

If intestinal ultrasound shows mild isolated hyperemia even with normal bowel wall thickness, this study found a higher chance of treatment changes, steroid use, surgery, or hospitalization within a year — information...

This study highlights changing patterns of IBD presentation and treatment over 26 years in a large Hispanic cohort, which may affect outcomes and access-to-care discussions for Hispanic patients.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from Journal of Crohn's & colitis.

This study suggests heated-tobacco products (and possibly e-cigarettes) may increase the risk of endoscopic recurrence after ileocolic resection for Crohn’s disease, which could affect postoperative outcomes and...

Ustekinumab is already approved for moderate-to-severe Crohn's disease; this real-world study reports encouraging longer-term clinical, biological, and endoscopic outcomes up to 96 weeks and suggests good treatment...

This study explores a potential mechanism linking a MAP infection model to inflammatory and metabolic pathways relevant to Crohn’s disease and tests whether methylglyoxal can lessen inflammatory programming in...

Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from Inflammatory bowel...

Drug levels and how patients reach remission can differ depending on prior biologic use. For families and clinicians managing pediatric Crohn's, this can affect how infliximab dosing and monitoring are interpreted after...

The study points to a specific immune cell type (pro-inflammatory CD4+ macrophages) and altered cellular interactions in rectal tissue that are linked to perianal fistulizing Crohn's disease, which may help explain...

Persistent perineal sinus is a common and impactful complication after proctectomy for Crohn disease that can prolong recovery and require further care. Knowing rates of healing and risk factors can help patients and...

This deal accelerates funding for a drug (RXC008) specifically targeting fibrosis in Crohn’s disease, an area with no approved anti‑fibrotic therapies and where patients often need surgery for strictures. If clinical...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease and Research and clinical trials.

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Stricture.

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from gastroendonews.com.